23andMe
NEWS
23andMe raised $592 million in proceeds from the IPO and, as of September 30, had about $700 million. With that cash in hand, it plans to push faster and deeper into drug development.
This year’s top 30 large and small companies operate in some of the Life Sciences’ hottest spaces – precision medicine, vaccines, gene editing, genomics and oncology.
Many mergers took place in 2021. Here’s a look at some of the hottest life sciences SPAC merger announcements so far in 2021. Many mergers took place in 2021,
Wanting to find out what is fueling the trend, BioSpace solicited the perspectives of a couple of executives who chose the SPAC route.
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industry is still booming coming out of the COVID-19 pandemic.
With 2020 holding a record number of biotech IPOs, this year is lining up to come close. Three more Bay Area life science companies are just about ready to hit the Nasdaq, adding to the growing list for 2021.
The cash just keeps coming for biopharma companies. Here’s a rundown of some of this week’s investment dollar recipients.
Billionaire Sir Richard Branson believes in healthcare. This week he put more of his money where his mouth is by using his SPAC to take consumer DNA testing company 23andMe public in a massive deal.
The layoffs are in departments across the company that aren’t central to its consumer testing and therapeutics business.
JOBS
IN THE PRESS